2 edition of Aspects of hepatic arterial chemotherapy in the treatment of colorectal liver metastases found in the catalog.
Aspects of hepatic arterial chemotherapy in the treatment of colorectal liver metastases
Jacqueline Ann Goldberg
Thesis (M.D.)- University of Birmingham, Faculty of Medicine and Dentistry.
|Statement||by Jacqueline AnnGoldberg.|
Read "Hepatic arterial chemotherapy of liver metastases from colorectal cancer: Treatment results, limitations and future aspects, European Surgery" on DeepDyve, . INTRODUCTION — Colorectal cancer (CRC) is estimated to affect , individuals in the United States in , and over one-half of these patients will develop liver metastases at some those, only 20 percent will be candidates for potentially curative liver resection. Long-term survival after surgery for colorectal liver metastases .
Approximately , new cases of colorectal carcinoma are diagnosed annually. Of these patients, 15‐25% present with metastatic disease in the liver at the time of the original diagnosis; another 25% develop metastasis later in the course of their disease. 1 The median survival after the diagnosis of hepatic metastasis is 6 months. Hepatic resection is the treatment Cited by: This book is a tool for professionals (general and cancer surgeons, HPB surgeons, clinical oncologists, gastroenterologists and medical residents) and interns who search for a qualified and reader friendly revision on topics concerning Colorectal Cancer Liver Metastases.
Overview: Treatment strategies for patients with stage IV colorectal cancer have changed markedly in the last decade. Patients with colorectal cancer metastases to the liver have always been a fascinating group to consider biologically and for local-regional treatment Author: Steven A. Curley. David Kerr and colleagues (Feb 1, p )1 have made a valuable contribution to the debate on the role of hepatic artery chemotherapy in colorectal liver metastases. We agree with their conclusion that the intra-arterial Author: Adam Brooks, Philip Clingan, David Morris.
New Millennium Writings
The Bible in Spain
Handlist of parish records.
Fishing vessel subsidies.
UK personal computer market.
Low Impact Development Conference 2007
Revolution by evolution
Conrad in quest of his youth
France and Europe.
Understanding the Dalai Lama
On wandering wheels
Rome painted by Alberto Pisa
Introduction. Colorectal cancer is one of the most common malignancies, with one million new cases each year worldwide.1 Liver metastases are detected in 40% to 60% of patients with colorectal carcinoma and in one third of the cases it is the sole site of disease.2–4 If untreated, the median survival of patients with hepatic metastases is 6 to 12 months.5–7 Hepatic Cited by: 9.
Resection of colorectal liver metastases is a treatment standard because patients experience long-term disease-free survival or are even cured after undergoing this procedure.
Improved surgical techniques for liver resection in combination with downsizing liver metastases by chemotherapy, interventions to induce liver Cited by: 1. Hepatic Arterial Chemotherapy for Colorectal Liver Metastases. Abstract. The liver is the site of metastatic spread from colorectal cancer in 40% of patients 1.
Unfortunately, only 10% of these patients will have tumours which are amenable to surgery Cited by: 5. Abstract Background: For more than three decades, hepatic arterial chemotherapy (HAI) has been used in the treatment of liver metastases from colorectal cancer. This approach.
Abstract. Hepatic arterial infusion (HAI) refers to infusional chemotherapy delivered through the hepatic artery for the treatment of primary and secondary liver malignancies. In colorectal cancer liver metastases, HAI has been extensively studied over the last several decades.
The combination of HAI and systemic chemotherapy Author: Camilo Correa-Gallego, Michael I. D’Angelica. Background: For more than three decades, hepatic arterial chemotherapy (HAI) has been used in the treatment of liver metastases from colorectal approach achieves significantly higher concentrations of various cytotoxic agents within the hepatic Author: Birgit Schüll, W.
Scheithauer. Hepatic intra-arterial therapies for hmCRC are intuitively attractive because the blood supply to liver metastases is almost exclusively via the hepatic arteries, whereas vascularization of normal liver parenchyma is 70% portal and 30% arterial.
8 Catheter-based hepatic intra-arterial therapies thus preferentially deliver therapeutic agents to metastatic foci while minimizing systemic exposure and treatment-associated Cited by: A large series of consecutive patients who underwent treatment for hepatic colorectal metastases with resection or RFA, or both, demonstrated that overall survival was highest after resection (58% at 5 years) compared with the RFA-only group, whose survival tracked close to that of patients treated with chemotherapy Cited by: The technique of hepatic arterial infusion (HAI) for the treatment of liver metastases from colorectal cancer has been developed over more than 30 years.
Although the indications and Cited by: 8. The rationale for hepatic intra-arterial chemotherapy (HACT) is based on the predominantly arterial vascularization of liver metastases (HM). The intra-arterial route of administration Cited by: 4. The study of hepatic arterial infusion of chemotherapy after resection of hepatic metastases in patients with colorectal cancer, reported by Kemeny et al.
(Dec. 30 issue), 1 represents a. This book presents a comprehensive coverage of colorectal cancer liver metastases.
Chapters display introductory topics, basic science subjects and practical clinical aspects for general. Established hepatic metastases derive their blood supply largely from the hepatic artery, whereas normal liver cells derive most of their blood supply from the portal vein.
8 Since Cited by: Introduction. There are overcases of colorectal cancer yearly in the USA. Approximately 60% will develop liver metastases (CRLM).
1 Complete resection of hepatic-only metastases Cited by: Hepatic arterial infusion chemotherapy (HAIC) is a treatment used for liver metastases (LM) of colorectal cancer (CRC). Because of its technical conditions, it has been used in only a Cited by: 8.
Fiorentini G, Cantore M, Rossi S, et al. Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal Cited by: 4. Hepatic arterial infusion (HAI) refers to infusional chemotherapy delivered through the hepatic artery for the treatment of primary and secondary liver malignancies.
There are several unique aspects of hepatic arterial chemotherapy, making it a treatment modality that is both rational and of great therapeutic potential (Table 1). Recent developments have defined the prerequisites for successful hepatic arterial chemotherapy Cited by: 2.
Liver metastases from colorectal cancer (CRC) result in substantial morbidity and mortality. The primary treatment is systemic chemotherapy, and in selected patients, surgical resection; however, for patients who are not surgical candidates and/or fail systemic chemotherapy Cited by: The prognosis of resectable colorectal liver metastases (CRLM) was improved in the recent years with the consideration of chemotherapy and surgical resection as part of the.
Hepatic arterial infusion (HAI) chemotherapy has been used over the last 30 years in patients with liver metastases from colorectal cancer and intrahepatic cholangiocarcinoma.1.
Introduction. It has been estimated thatnew cases of colon cancer will be diagnosed in the year It is further estimated that o people will die of this disease during the same time imately 60% of colon cancer patients will develop hepatic ering that 20–33% of all colon cancer patients die of metastases confined to the liver Cited by: Colorectal cancer is the third most common cancer and the third leading cause of mortality among men and women.
Inthere will be an estimatednew cases and an estima deaths from colorectal cancer. 1 Approximately 30% to 50% of patients with this disease will develop liver metastases Cited by: